SIGLEC10 and cancer: This dramatic shift of TAMs is benefit in modulating the TME and promoting ICIs treatment against cancers.410 Many macrophage-targeting agents have been developed with different approaches for cancer therapy, including previously unmentioned CXCL12-CXCR4 inhibitors, TREM inhibitors, SIGLEC10-CD24 inhibitors, and TLR agonists.404